VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial.
Saved in:
| Title: | VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. |
|---|---|
| Authors: | Swaminathan M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mswaminathan@mdanderson.org., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kornblau SM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pierce SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Apr 02; Vol. 15 (1), pp. 52. Date of Electronic Publication: 2025 Apr 02. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-025-01265-1 |
